- Home
- ABUS vs AVNS Comparison
ABUS vs AVNS Comparison
Compare ABUS & AVNS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ABUS
- AVNS
- Stock Information
- Founded
- ABUS 2005
- AVNS 2014
- Country
- ABUS United States
- AVNS United States
- Employees
- ABUS N/A
- AVNS N/A
- Industry
- ABUS Biotechnology: Pharmaceutical Preparations
- AVNS Industrial Specialties
- Sector
- ABUS Health Care
- AVNS Health Care
- Exchange
- ABUS Nasdaq
- AVNS Nasdaq
- Market Cap
- ABUS 711.2M
- AVNS 591.9M
- IPO Year
- ABUS N/A
- AVNS N/A
- Fundamental
- Price
- ABUS $4.20
- AVNS $12.71
- Analyst Decision
- ABUS Strong Buy
- AVNS
- Analyst Count
- ABUS 3
- AVNS 0
- Target Price
- ABUS $5.67
- AVNS N/A
- AVG Volume (30 Days)
- ABUS 1.0M
- AVNS 724.7K
- Earning Date
- ABUS 11-05-2025
- AVNS 10-29-2025
- Dividend Yield
- ABUS N/A
- AVNS N/A
- EPS Growth
- ABUS N/A
- AVNS N/A
- EPS
- ABUS N/A
- AVNS N/A
- Revenue
- ABUS $15,416,000.00
- AVNS $692,500,000.00
- Revenue This Year
- ABUS $138.02
- AVNS $0.25
- Revenue Next Year
- ABUS N/A
- AVNS $1.33
- P/E Ratio
- ABUS N/A
- AVNS N/A
- Revenue Growth
- ABUS 53.23
- AVNS 1.48
- 52 Week Low
- ABUS $2.71
- AVNS $9.30
- 52 Week High
- ABUS $4.73
- AVNS $25.36
- Technical
- Relative Strength Index (RSI)
- ABUS 84.85
- AVNS 68.80
- Support Level
- ABUS $3.60
- AVNS $11.68
- Resistance Level
- ABUS $4.10
- AVNS $12.00
- Average True Range (ATR)
- ABUS 0.17
- AVNS 0.37
- MACD
- ABUS 0.06
- AVNS 0.17
- Stochastic Oscillator
- ABUS 83.33
- AVNS 85.03
About ABUS Arbutus Biopharma Corporation
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes an RNAi therapeutic, imdusiran (AB-729), and an oral PD-L1 inhibitor, AB-101. In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.
About AVNS Avanos Medical Inc.
Avanos Medical Inc is a United States-based company that develops and sells medical devices and related services globally. Its operating and reportable segment provides medical device products to healthcare providers and patients. The company has now changed two franchises: has combined Chronic Care and Pain Management franchises into a single commercial organization focused on the Digestive Health and Pain Management and Recovery product categories that generate its revenue from its Chronic Care franchise and in North America.